Literature DB >> 36210389

An eleven autophagy-related genes-based prognostic signature for endometrial carcinoma.

Shiyang Li1, Junan Pan2, Yanyu Zhang3, Yan Tang4, Xiaobing Zeng2, Shihai Wang2, Dengxuan Wu2, Yuyong Liu2, Dawen Xu2, Jianjun Lan2, Dong Hu5.   

Abstract

BACKGROUND: Endometrial cancer (EC) is a common malignant tumor in women with increasing mortality. The prognosis of EC is highly heterogeneous which needs more effective biomarkers for clinical decision. Here, we reported the effect of autophagy-related genes (ARGs) on the prognosis of EC.
METHODS: The expression data of EC tissues and adjacent non-tumor samples were available from the TCGA dataset and 232 autophagy-related genes were from The Human Autophagy Database. A prognostic ARGs risk model was further constructed by using LASSO-Cox regression, and its prognostic and predictive value were evaluated by nomogram. Further functional analysis was conducted to reveal a significant signaling pathway.
RESULTS: A total of 45 differentially expressed ARGs were obtained, including 18 upregulated and 27 downregulated genes. Eleven ARGs (BID, CAPN2, CDKN2A, DLC1, GRID2, IFNG, MYC, NRG3, P4HB, PTK6, and TP73) were finally selected to build ARGs risk. This signature could well distinguish between the high- and low-risk patients (survival analysis: P = 1.18E-10; AUC: 0.733 at 1 year, 0.795 at 3 years, and 0.823 at 5 years). Furthermore, a nomogram was plotting to predict the possibility of overall survival and suggested good value for clinical utility.
CONCLUSION: We established an eleven-ARG signature, which was probably effective in the prognostic prediction of patients with EC.
© 2022. The Author(s).

Entities:  

Keywords:  Autophagy; Endometrial cancer; Prognosis; The Cancer genome atlas

Mesh:

Substances:

Year:  2022        PMID: 36210389     DOI: 10.1186/s43046-022-00135-2

Source DB:  PubMed          Journal:  J Egypt Natl Canc Inst        ISSN: 1110-0362


  29 in total

Review 1.  Endometrial cancer: Molecular markers and management of advanced stage disease.

Authors:  Rebecca C Arend; Bayley A Jones; Alba Martinez; Paul Goodfellow
Journal:  Gynecol Oncol       Date:  2018-05-27       Impact factor: 5.482

2.  [Use of pentazocine for anesthesia maintenance].

Authors:  T Isa; E Yamamoto; T Ozaki; K Kajiwara; T Morioka
Journal:  Masui       Date:  1970-12

Review 3.  Endometrial Cancer.

Authors:  Karen H Lu; Russell R Broaddus
Journal:  N Engl J Med       Date:  2020-11-19       Impact factor: 91.245

4.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

5.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

6.  Cross-cancer profiling of molecular alterations within the human autophagy interaction network.

Authors:  Chandra B Lebovitz; A Gordon Robertson; Rodrigo Goya; Steven J Jones; Ryan D Morin; Marco A Marra; Sharon M Gorski
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

7.  PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy.

Authors:  Hua Liu; Liqin Zhang; Xuyan Zhang; Zhumei Cui
Journal:  Onco Targets Ther       Date:  2017-06-06       Impact factor: 4.147

8.  Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.

Authors:  Núria Eritja; Bo-Juen Chen; Ruth Rodríguez-Barrueco; Maria Santacana; Sònia Gatius; August Vidal; Maria Dolores Martí; Jordi Ponce; Laura Bergadà; Andree Yeramian; Mario Encinas; Joan Ribera; Jaume Reventós; Jeff Boyd; Alberto Villanueva; Xavier Matias-Guiu; Xavier Dolcet; David Llobet-Navàs
Journal:  Autophagy       Date:  2017-01-05       Impact factor: 16.016

9.  Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

Authors:  I Ray-Coquard; L Favier; B Weber; C Roemer-Becuwe; P Bougnoux; M Fabbro; A Floquet; F Joly; A Plantade; D Paraiso; E Pujade-Lauraine
Journal:  Br J Cancer       Date:  2013-04-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.